Sarah Ketterer
Causeway Capital Management
Sarah Ketterer Pfizer Inc stake
total: 372
Causeway Capital Management PFE trades
- Total transactions:
- 9
- New positions:
- 1
- Added:
- 5
- Reduced:
- 3
- Held since:
- 2024 Q2
- Held for:
- 9 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Sarah Ketterer holds 1,916,801 Pfizer Inc (PFE) shares with a market value of roughly $46.16M accounting for 0.50% of the overall portfolio. To date, the estimated cost basis is nearly $27.72 for "buy" trades and estimated average "sell" price is $26.75. Causeway Capital Management first purchased PFE in 2024 Q2, initially acquiring about 2.00M shares. Since the initial investment in Pfizer Inc (PFE), Causeway Capital Management has made 8 more transactions.
When did Sarah Ketterer buy Pfizer Inc (PFE)?
Sarah Ketterer first invested in Pfizer Inc (PFE) in 2024 Q2 at the reported quarter-end price of $27.98 per share.
What's the cost basis of Causeway Capital Management's PFE stake?
The estimated cost basis for Pfizer Inc (PFE) stake is around $27.72 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $27.72
- Weighted AVG sell price:
- $26.75
Sarah Ketterer's historical trades in Pfizer Inc
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.50%
|
1,916,801
|
$24.08
|
$46,156,576
|
+0.13% (+2,582)
|
+0%
|
|
2026 Q1
|
0.66%
|
1,914,219
|
$28.08
|
$53,751,301
|
-8.49% (-177,500)
|
-0.07%
|
|
2025 Q4
|
0.72%
|
2,091,719
|
$24.90
|
$52,083,825
|
+0.95% (+19,672)
|
+0.01%
|
|
2025 Q3
|
0.70%
|
2,072,047
|
$25.48
|
$52,795,723
|
+5.54% (+108,735)
|
+0.04%
|
|
2025 Q2
|
0.75%
|
1,963,312
|
$24.24
|
$47,590,657
|
-3.01% (-60,943)
|
-0.03%
|
|
2025 Q1
|
1.07%
|
2,024,255
|
$25.34
|
$51,294,627
|
+10.45% (+191,465)
|
+0.1%
|
|
2024 Q4
|
1.11%
|
1,832,790
|
$26.53
|
$48,623,947
|
-17.12% (-378,520)
|
-0.25%
|
|
2024 Q3
|
1.57%
|
2,211,310
|
$28.94
|
$63,995,300
|
+10.36% (+207,651)
|
+0.15%
|
|
2024 Q2
|
1.53%
|
2,003,659
|
$27.98
|
$56,062,368
|
new
|
+1.53%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.